Modopar 62,5 (Benserazide Hydrochloride, Levodopa)

Levodopa is a dopamine precursor that crosses the blood‑brain barrier and is converted to dopamine in the central nervous system. Benserazide inhibits the peripheral enzyme dopa decarboxylase, preventing premature conversion of levodopa outside the brain and thereby enhancing its central availability.

The specific dose of Modopar 62,5 is determined by the prescribing clinician based on the individual’s disease severity, response to therapy, and tolerability. Patients should follow the dosage instructions provided by their healthcare professional.

The safety of Modopar 62,5 in pregnancy or while breastfeeding has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Modopar 62,5 combines levodopa with benserazide, offering a direct dopamine replacement strategy. Compared with dopamine agonists, it generally provides more robust symptom control but may have a higher risk of motor complications such as dyskinesia. Choice of therapy depends on individual patient factors and physician judgment.

Store Modopar 62,5 tablets at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Modopar 62,5 is taken orally, usually with a glass of water. It may be taken with or without food, but consistent timing relative to meals can help minimize gastrointestinal side effects. Patients should follow the dosing schedule prescribed by their clinician.

Serious risks include severe hypotension, neuroleptic malignant syndrome, significant dyskinesia, and psychiatric disturbances such as hallucinations or psychosis. Patients should be monitored closely for these events, and any sudden or severe symptoms should prompt immediate medical evaluation.

Modopar 62,5 is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients, and in those taking non‑selective MAO inhibitors. Caution is also advised for individuals with a history of severe cardiovascular disease, uncontrolled hypertension, or psychiatric disorders.